Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Lane

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
Angewandte Chemie (International Ed. in English)|February 10, 2024
Discovery of the First-in-Class Inhibitors of Hypoxia Up-Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast ActivationDimitra Papadopoulou, Vasiliki Mavrikaki, Filippos Charalampous, et al.
Molecular Pharmacology|August 6, 2021
Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D<sub>2</sub> Dopamine ReceptorR Benjamin Free, Caroline A Cuoco, Bing Xie, et al.
Iscience|August 19, 2022
Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptineDespoina Aslanoglou, Suzanne Bertera, Laura Friggeri, et al.
Breast Cancer Research : BCR|November 27, 2015
β2-adrenoceptor signaling regulates invadopodia formation to enhance tumor cell invasionSarah J Creed, Caroline P Le, Mona Hassan, et al.
Nature|October 15, 2013
Structural basis for modulation of a G-protein-coupled receptor by allosteric drugsRon O Dror, Hillary F Green, Celine Valant, et al.
European Journal of Medicinal Chemistry|June 26, 2026
Dual-target mu opioid-dopamine D<sub>3</sub> receptor (MOR-D<sub>3</sub>R) ligands based on etonitazene: New leads for transforming "nitazenes" into novel analgesicsKhorshada Jahan, Grant Glatfelter, Julie Sanchez, et al.
Molecular Pharmacology|August 3, 2018
Identification of Positive Allosteric Modulators of the D<sub>1</sub> Dopamine Receptor That Act at Diverse Binding SitesKathryn D Luderman, Jennie L Conroy, R Benjamin Free, et al.
Journal of Pediatric Orthopedics|September 11, 2024
Reliability of a Photo-Based Modified Foot Posture Index (MFPI) in Quantifying Severity of Foot Deformity in Children With Cerebral PalsyAndrew G Georgiadis, Jon R Davids, Christine M Goodbody, et al.
Science Signaling|April 3, 2020
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonistsAlexander Gillis, Arisbel B Gondin, Andrea Kliewer, et al.
ACS Pharmacology & Translational Science|January 19, 2023
Identification and Characterization of ML321: A Novel and Highly Selective D<sub>2</sub> Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic ActivityR Benjamin Free, Ashley N Nilson, Noelia M Boldizsar, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Angewandte Chemie (International Ed. in English)|February 10, 2024
Discovery of the First-in-Class Inhibitors of Hypoxia Up-Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast ActivationDimitra Papadopoulou, Vasiliki Mavrikaki, Filippos Charalampous, et al.
Molecular Pharmacology|August 6, 2021
Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D<sub>2</sub> Dopamine ReceptorR Benjamin Free, Caroline A Cuoco, Bing Xie, et al.
Iscience|August 19, 2022
Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptineDespoina Aslanoglou, Suzanne Bertera, Laura Friggeri, et al.
Breast Cancer Research : BCR|November 27, 2015
β2-adrenoceptor signaling regulates invadopodia formation to enhance tumor cell invasionSarah J Creed, Caroline P Le, Mona Hassan, et al.
Nature|October 15, 2013
Structural basis for modulation of a G-protein-coupled receptor by allosteric drugsRon O Dror, Hillary F Green, Celine Valant, et al.
European Journal of Medicinal Chemistry|June 26, 2026
Dual-target mu opioid-dopamine D<sub>3</sub> receptor (MOR-D<sub>3</sub>R) ligands based on etonitazene: New leads for transforming "nitazenes" into novel analgesicsKhorshada Jahan, Grant Glatfelter, Julie Sanchez, et al.
Molecular Pharmacology|August 3, 2018
Identification of Positive Allosteric Modulators of the D<sub>1</sub> Dopamine Receptor That Act at Diverse Binding SitesKathryn D Luderman, Jennie L Conroy, R Benjamin Free, et al.
Journal of Pediatric Orthopedics|September 11, 2024
Reliability of a Photo-Based Modified Foot Posture Index (MFPI) in Quantifying Severity of Foot Deformity in Children With Cerebral PalsyAndrew G Georgiadis, Jon R Davids, Christine M Goodbody, et al.
Science Signaling|April 3, 2020
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonistsAlexander Gillis, Arisbel B Gondin, Andrea Kliewer, et al.
ACS Pharmacology & Translational Science|January 19, 2023
Identification and Characterization of ML321: A Novel and Highly Selective D<sub>2</sub> Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic ActivityR Benjamin Free, Ashley N Nilson, Noelia M Boldizsar, et al.
Pageof 15